222. 一次性ネフローゼ症候群 ［臨床試験数：234，薬物数：241（DrugBank：78），標的遺伝子数：59，標的パスウェイ数：185］
Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|1||ChiCTR2000037467||2020-12-31||2020-08-28||Effect of Tripterygium wilfordii polyglycoside tablets on the inhibition of TM on complement pathway and related inflammatory markers in membranous nephropathy||The complement pathway and related inflammatory factor markers in the treatment of idiopathic membranous nephropathy||idiopathic membranous nephropathy||Gold Standard:Cell hemolysis test;Index test:Immunochemiluminescence (ECL) and flow cytometry (FCM) were used to determine the activity of each complement pathway and the target of complement;|
Complement hemolysis test is usually used to determine the activity of total complement and single complement component, but it is difficult to be applied to clinical ;
|Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine||NULL||Pending||18||80||Both||Target condition:40;Difficult condition:40||China|
|2||NCT04387448||July 28, 2020||11/5/2020||A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease||A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease||Kidney Diseases;Diabetic Nephropathies;Glomerulosclerosis, Focal Segmental;Nephrosis, Lipoid;Urologic Diseases;Diabetes Complications;Diabetes Mellitus;Endocrine System Diseases;Glomerulonephritis;Nephritis;Nephrosis||Drug: GFB-887;Drug: Placebo||Goldfinch Bio, Inc.||NULL||Recruiting||18 Years||75 Years||All||125||Phase 2||United States|
|3||ChiCTR1900027128||2019-10-30||2019-11-01||Validation of Anti-Phospholipase A2 Receptor Antibody ELISA in a Chinese Cohort With Idiopathic Membranous Nephropathy: a Multicenter Observational Study||The Cut-off Value of Anti-Phospholipase A2 Receptor Antibody ELISA in Chinese Patients||Membranous Nephrology||Gold Standard:Pathological diagnosis according to kidney biopsy(Chapter 7, 7.1 Evaluation of MN, KDIGO 2012);Index test:Serum PLA2R Antibody by ELISA;||Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University||NULL||Recruiting||Both||Target condition:288;Difficult condition:290||N/A||China|